About Cytodyn Inc
- Industry: Biotechnology
- Exchange: OTC MARKETS
- Country: US
- Website: https://www.cytodyn.com/
Frequently Asked Questions
What is the 52-week range for CYDY?
The 52-week high is $0.397 and the 52-week low is $0.1829.
What is the P/E ratio for CYDY?
The P/E ratio data is currently unavailable.
What is the dividend yield for CYDY?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -1113.87%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 11.94.
Analyst Recommendation Trends
Wall Street analyst consensus for CYDY over the last few months:
Latest CYDY News
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
CytoDyn (OTCMKTS:CYDY) Chief Financial Officer Robert E. Hoffman outlined the company’s clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors. Speaking at the Life
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the September 17th Life Sciences Virtual Investor Forum are available for on-demand viewing. The event featured live presentations from executives representing innovative clinical-stage and commercial companies across the life sciences sector. REGIS
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E. Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Fo
Life Sciences Virtual Investor Forum Agenda Announced
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Forum taking place on September 17, 2026. REGISTER HERE Individual investors, institutional investors, advisors, and analysts are invited to attend. It is rec
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-03-20 | Urbach Tanya Durkee | +574,385 | - | - |
| 2026-03-20 | SIMES STEPHEN M | +574,385 | - | - |
| 2026-03-20 | Ndhlovu Lishomwa C | +574,385 | - | - |
| 2026-03-20 | Lalezari Jacob P | +4,874,691 | - | - |
| 2026-03-20 | Dunlap Ryan | +574,385 | - | - |
| 2026-03-20 | Brunke Karen J | +574,385 | - | - |
| 2026-03-20 | Blok Tyler | +3,249,794 | - | - |
| 2026-03-20 | Hoffman Robert E. | +4,874,691 | - | - |